{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:02:40Z","timestamp":1789722160521,"version":"4.0.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Pioglitazone is thought to increase the risk of heart failure exacerbation in vulnerable individuals, primarily through fluid retention and plasma volume expansion. However, the precise molecular and cellular mechanisms remain incompletely understood. This narrative review aims to collect, organise, and evaluate current evidence on the pathophysiological mechanisms driving pioglitazone-related heart failure. We categorised preclinical and clinical data into key pathophysiological domains and graded evidence strength as high, moderate, or limited. The key domains implicated in this process include renal fluid retention, direct myocardial effects, altered energy metabolism, vascular changes, neurohormonal activation, and individual genetic susceptibility. While fluid retention and vascular changes demonstrate strong clinical evidence, direct myocardial toxicity remains primarily observed\n                    <jats:italic>in vitro<\/jats:italic>\n                    and lacks clinical confirmation. Neurohormonal activation and metabolic disturbances are supported by moderate evidence from animal models and cohort studies, whereas evidence for genetic susceptibility and direct cardiotoxicity remains limited. Overall, this review grades the strength of current evidence and provides a framework for the safe clinical use of pioglitazone and the design of targeted risk prevention strategies.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2026.1843086","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:22:06Z","timestamp":1789719726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress on the pathophysiological mechanisms of pioglitazone-induced heart failure: a review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jianli","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1111\/dom.15222","article-title":"In praise of pioglitazone: a multifaceted insulin sensitiser","volume":"25","author":"Bell","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug","volume":"20","author":"Nesti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e46911","DOI":"10.7759\/cureus.46911","article-title":"Association of pioglitazone with major adverse cardiovascular events and heart failure: a systematic review and meta-analysis","volume":"15","author":"Sheikh","year":"2023","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"15781","DOI":"10.1038\/s41598-020-72967-8","article-title":"Assessing the need for pioglitazone in the treatment of type 2 diabetes in the context of cardiovascular outcome trials: a meta-analysis","volume":"10","author":"Sinha","year":"2020","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/jat.4613","article-title":"Cytotoxicity and toxicoproteomics analysis of thiazolidinedione exposure in human-derived cardiomyocytes","volume":"44","author":"Sultan","year":"2024","journal-title":"J Appl Toxicol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11306-024-02097-z","article-title":"Toxicometabolomics-based cardiotoxicity evaluation of thiazolidinediones in human-derived cardiomyocytes","volume":"20","author":"Sultan","year":"2024","journal-title":"Metabolomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e53400","DOI":"10.7759\/cureus.53400","article-title":"Etiology of drug-induced edema: a comprehensive review","volume":"16","author":"Sinnathamby","year":"2024","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.numecd.2021.12.006","article-title":"Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"32","author":"Mannucci","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12471-021-01579-2","article-title":"The effects of antidiabetic agents on heart failure: a narrative review","volume":"30","author":"Wijnen","year":"2022","journal-title":"Neth Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1536\/ihj.21-404","article-title":"Pioglitazone protects against hypoxia-induced cardiomyocyte apoptosis by blocking the NLRP3\/caspase-1 signaling pathway","volume":"63","author":"Zhang","year":"2022","journal-title":"Int Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0226999","DOI":"10.1371\/journal.pone.0226999","article-title":"Post mortem evaluation of inflammation, oxidative stress, and PPAR\u03b3 activation in a nonhuman primate model of cardiac sympathetic neurodegeneration","volume":"15","author":"Metzger","year":"2020","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"174076","DOI":"10.1016\/j.ejphar.2021.174076","article-title":"Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention and cardiac hypertrophy in type 2 diabetic mice with NASH","volume":"901","author":"Tahara","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"110685","DOI":"10.1016\/j.diabres.2023.110685","article-title":"Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: a real-world cohort study","volume":"200","author":"Lo","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1111\/dom.15576","article-title":"Effect of combination pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists on cardiovascular outcomes in type 2 diabetes: a systematic review and meta-analysis","volume":"26","author":"Anson","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e15535","DOI":"10.14814\/phy2.15535","article-title":"PPARG agonist pioglitazone influences diurnal kidney medulla mRNA expression of core clock genes and ENaC subunits in mice","volume":"10","author":"Izmailova","year":"2022","journal-title":"Physiol Rep"},{"key":"B17","first-page":"333","article-title":"Management of type 2 diabetes mellitus with noninsulin pharmacotherapy","volume":"109","author":"Vaughan","year":"2024","journal-title":"Am Fam Physician"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101681","DOI":"10.1016\/j.jbc.2022.101681","article-title":"Oxidized alkyl phospholipids stimulate sodium transport in proximal tubules through a non-genomic PPAR\u03b3-dependent pathway","volume":"298","author":"Mizuno","year":"2022","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e240485","DOI":"10.20945\/2359-4292-2024-0485","article-title":"Effect of SGLT2 inhibitors on thiazolidinedione-induced changes in volume status in patients with type 2 diabetes","volume":"69","author":"Unlusoy","year":"2025","journal-title":"Arch Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/dom.70356","article-title":"Sodium-glucose cotransporter 2 inhibitor ameliorates thiazolidinedione-induced fluid retention by protecting white adipose tissue vascular integrity","volume":"28","author":"Kim","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1021\/acs.molpharmaceut.9b01131","article-title":"Pioglitazone increases blood-brain barrier expression of fatty acid-binding protein 5 and plasma volume expansion markers","volume":"17","author":"Low","year":"2020","journal-title":"Mol Pharm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10753-022-01716-y","article-title":"Hyperglycemia aggravates blood-brain barrier disruption following diffuse axonal injury and increases vascular permeability","volume":"46","author":"Wei","year":"2023","journal-title":"Inflammation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/medsci11030050","article-title":"Review of the case reports on metformin, sulfonylurea, and thiazolidinedione therapies: focus on adverse events","volume":"11","author":"Susilawati","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70035","DOI":"10.1002\/iub.70035","article-title":"Modulation of PPAR-\u03b1 and PPAR-\u03b3 influences cardiomyocyte growth and cardiac remodeling","volume":"77","author":"Xuan","year":"2025","journal-title":"IUBMB Life"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke: a post-hoc analysis of the IRIS trial","volume":"24","author":"Spence","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.15.694265","article-title":"Small molecule inhibitor of PPAR\u03b3 acetylation promotes insulin sensitization and browning of white adipose tissue with improved safety","author":"Wu","year":"2025","journal-title":"bioRxiv : The Preprint Server for Biology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ajpath.2024.02.009","article-title":"Metallothionein alleviates glutathione depletion-induced oxidative cardiomyopathy and contractile dysfunction in mice","volume":"194","author":"Li","year":"2024","journal-title":"Am J Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1111\/dom.15251","article-title":"Cardiovascular efficacy and safety of antidiabetic agents: a focus on heart failure","volume":"25","author":"Sohn","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3350\/cmh.2022.0237","article-title":"Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis: role of PPAR\u03b3 agonists","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7570\/jomes25017","article-title":"Metabolic dysfunction-associated steatotic liver disease complicated by diabetes: pPAR\u03b3 as a therapeutic target","volume":"34","author":"Goto","year":"2025","journal-title":"J Obes Metab Syndr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.2174\/0109298673308673240527092317","article-title":"Pioglitazone alleviates \u03b21-adrenergic receptor antibody-induced atrial fibrillation susceptibility by improving energy metabolism","volume":"32","author":"Xi","year":"2025","journal-title":"Curr Med Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11306-024-02201-3","article-title":"Integrative analysis of toxicometabolomics and toxicoproteomics data reveals multi-level cardiotoxicity mechanisms of thiazolidinediones","volume":"21","author":"Sultan","year":"2024","journal-title":"Metabolomics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"658362","DOI":"10.3389\/fphar.2021.658362","article-title":"Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial dynamics","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e70109","DOI":"10.1111\/cpr.70109","article-title":"Pioglitazone ameliorates mitochondrial oxidative stress and inflammation in myocardial ischemia-reperfusion injury","volume":"59","author":"Luo","year":"2026","journal-title":"Cell Prolif"},{"key":"B35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuroscience.2020.02.035","article-title":"Activation of PGC-1\u03b1 and mitochondrial biogenesis by pioglitazone protects against prenatal hypoxic-ischemic brain injury","volume":"432","author":"Jia","year":"2020","journal-title":"Neuroscience"},{"key":"B36","doi-asserted-by":"publisher","first-page":"154416","DOI":"10.1016\/j.metabol.2020.154416","article-title":"Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in oxidative phosphorylation in insulin-resistant humans","volume":"114","author":"Fiorentino","year":"2021","journal-title":"Metab Clin Exp"},{"key":"B37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1055\/a-2178-9113","article-title":"Pioglitazone-enhanced brown fat whitening contributes to weight gain and is associated with mitochondrial dysfunction","volume":"131","author":"Yu","year":"2023","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/cells9010252","article-title":"PPAR\u03b3-independent side effects of thiazolidinediones on mitochondrial redox state in isolated rat hearts","volume":"9","author":"Riess","year":"2020","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8137","DOI":"10.1038\/s41598-025-87586-4","article-title":"Pharmacologic and endotoxic reprogramming of renal vasodilatory signaling: role of PPAR\u03b3","volume":"15","author":"Morgaan","year":"2025","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"175344","DOI":"10.1016\/j.ejphar.2022.175344","article-title":"Dysregulated ACE\/ang II\/Ang1\u20137 signaling provokes cardiovascular and inflammatory sequelae in septic offspring","volume":"936","author":"Abuiessa","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"E835","DOI":"10.1152\/ajpendo.00145.2020","article-title":"Worsening baroreflex sensitivity on progression to type 2 diabetes and its modulation by pioglitazone","volume":"319","author":"Bakkar","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00210-024-03305-2","article-title":"Gestationally administered RAS modulators reprogram endotoxic cardiovascular responses in adult rat offspring","volume":"398","author":"Abuiessa","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e70174","DOI":"10.14814\/phy2.70174","article-title":"Oral administration of pioglitazone inhibits pulmonary hypertension progression by modulating gut microbiome","volume":"13","author":"Zhang","year":"2025","journal-title":"Physiol Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"542146","DOI":"10.3389\/fphys.2020.542146","article-title":"Tribbles homolog 3-mediated vascular insulin resistance contributes to hypoxic pulmonary hypertension and is reversed by pioglitazone","volume":"11","author":"Fan","year":"2020","journal-title":"Front Physiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e14173","DOI":"10.1016\/j.heliyon.2023.e14173","article-title":"Activation of PPAR-\u03b3 prevents TERT-mediated pulmonary vascular remodeling in monocrotaline-induced pulmonary hypertension","volume":"9","author":"Hussain","year":"2023","journal-title":"Heliyon"},{"key":"B46","doi-asserted-by":"publisher","first-page":"113233","DOI":"10.1016\/j.biopha.2022.113233","article-title":"PPAR\u03b3 activation inhibits PDGF-induced pulmonary artery smooth muscle cell proliferation and migration through PTEN upregulation","volume":"152","author":"Zhang","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"B47","doi-asserted-by":"publisher","first-page":"178502","DOI":"10.1016\/j.ejphar.2025.178502","article-title":"SERCA2 dysfunction stimulates inflammation and causes pulmonary vascular remodeling: reversal by PPAR\u03b3 activation","volume":"1012","author":"Qiu","year":"2026","journal-title":"Eur J Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-025-03830-w","article-title":"Effects of oral antidiabetic agents on the renin-angiotensin-aldosterone system: a systematic review","volume":"81","author":"Yang","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/life13041024","article-title":"Anti-diabetic therapy and heart failure: recent advances and mechanistic insights","volume":"13","author":"Hsu","year":"2023","journal-title":"Life (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00210-023-02715-y","article-title":"Peroxisome proliferator activated receptor-gamma (PPAR-\u03b3) ligand, pioglitazone, increases analgesic and anti-inflammatory effects in formalin-induced nociception","volume":"397","author":"Haddadi","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.2147\/DDDT.S367229","article-title":"Protective effects of pioglitazone on cognitive impairment and neuroinflammation in a rat model of Alzheimer\u2019s disease","volume":"16","author":"Alhowail","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"566148","DOI":"10.3389\/fncel.2020.566148","article-title":"Pioglitazone ameliorates gentamicin ototoxicity by preserving mitochondrial function","volume":"14","author":"Sekulic-Jablanovic","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00011-025-02022-7","article-title":"Peroxisome proliferator-activated receptor gamma prevents activation of RBL-2H3 cells via suppressing NF-\u03baB signaling","volume":"74","author":"Zhang","year":"2025","journal-title":"Inflamm Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s11011-021-00741-4","article-title":"Possible role of rice bran extract in microglial modulation through PPAR-gamma receptors in a rat model of neuroinflammation","volume":"36","author":"El-Din","year":"2021","journal-title":"Metab Brain Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"9860855","DOI":"10.1155\/2022\/9860855","article-title":"Neuroprotective and anti-inflammatory effects of pioglitazone on traumatic brain injury: a review","volume":"2022","author":"Zamanian","year":"2022","journal-title":"Mediators Inflamm"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e23041","DOI":"10.1002\/jbt.23041","article-title":"Antiapoptotic and anti-inflammatory effects of PPAR\u03b3 agonist, pioglitazone, reversed doxorubicin-induced cardiotoxicity in rats","volume":"36","author":"Pakravan","year":"2022","journal-title":"J Biochem Mol Toxicol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"157694","DOI":"10.1016\/j.phymed.2025.157694","article-title":"Ginsenoside rd promotes cardiac regeneration through PPARG\/HMGCS2-driven ketone body metabolic reprogramming","volume":"150","author":"Zhang","year":"2026","journal-title":"Phytomedicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/FJC.0000000000001684","article-title":"Procyanidin B2 attenuates pathologic cardiac fibrosis and inflammation: role of PPAR\u03b3","volume":"85","author":"Li","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/03602532.2025.2508152","article-title":"An in-depth review of PPAR\u03b3 modulators as anti-diabetes therapeutics: from full agonists to selective modulators","volume":"57","author":"Jangra","year":"2025","journal-title":"Drug Metab Rev"},{"key":"B60","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12933-024-02358-0","article-title":"Prevalence and incidence of heart failure in type 2 diabetes patients: sex-specific differences","volume":"23","author":"Gonzalez-Manzanares","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1080\/14656566.2022.2143263","article-title":"Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes: a focus on pioglitazone","volume":"23","author":"Katsiki","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B62","doi-asserted-by":"publisher","first-page":"154892","DOI":"10.1016\/j.metabol.2021.154892","article-title":"Insulin resistance and insulin sensitizing agents: from pathophysiology to clinical practice","volume":"125","author":"Mastrototaro","year":"2021","journal-title":"Metab Clin Exp"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1765597","DOI":"10.3389\/fcdhc.2026.1765597","article-title":"Clinical and pathophysiological links between hypoglycemia and cardiovascular risk in patients with diabetes","volume":"7","author":"Ferhatbegovi\u0107","year":"2026","journal-title":"Front Clin Diabetes Healthc"},{"key":"B64","doi-asserted-by":"publisher","first-page":"9357","DOI":"10.3390\/ijms24119357","article-title":"Effects of hypoglycemia on cardiovascular function in patients with diabetes","volume":"24","author":"Christou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"111994","DOI":"10.1016\/j.mce.2023.111994","article-title":"Mitophagy disorder mediates cardiac deterioration induced by severe hypoglycemia in diabetic mice","volume":"575","author":"Huang","year":"2023","journal-title":"Mol Cell Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e72576","DOI":"10.7759\/cureus.72576","article-title":"Screening for occult heart failure in type 2 diabetes mellitus using NT-proBNP: a retrospective cross-sectional study","volume":"16","author":"Joshi","year":"2024","journal-title":"Cureus"},{"key":"B67","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/17446651.2023.2204941","article-title":"Treatment of type 2 diabetes patients with heart conditions: a practical approach","volume":"18","author":"Aktas","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.3390\/jcm14082733","article-title":"The impact of metformin on BNP levels in patients with type 2 diabetes","volume":"14","author":"Hoca","year":"2025","journal-title":"J Clin Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"175841","DOI":"10.1016\/j.ejphar.2023.175841","article-title":"Deoxyelephantopin\u2014a novel PPAR\u03b3 agonist regresses pressure overload-induced cardiac fibrosis and improves cardiac function","volume":"953","author":"Banik","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.eprac.2025.04.004","article-title":"Reassessing the risk-benefit profile of thiazolidinediones in the era of SGLT2 inhibitors and GLP-1 receptor agonists","volume":"31","author":"Fei","year":"2025","journal-title":"Endocr Pract"},{"key":"B72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/87551225251348838","article-title":"Pleural effusion and anasarca associated with pioglitazone: a case report","volume":"41","author":"Jagadish","year":"2025","journal-title":"J Pharm Technol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"94","DOI":"10.55729\/2000-9666.1541","article-title":"Unveiling an uncommon complication: pleural effusion secondary to pioglitazone use","volume":"15","author":"Chimauriya","year":"2025","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B74","doi-asserted-by":"publisher","first-page":"112139","DOI":"10.1016\/j.mce.2023.112139","article-title":"Canagliflozin improves fatty acid oxidation and ferroptosis in diabetic cardiomyopathy: implications for PPAR\u03b3 cross-talk","volume":"582","author":"Gan","year":"2024","journal-title":"Mol Cell Endocrinol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.ajmo.2025.100115","article-title":"The impact of different antidiabetic drugs on fracture risk and cardiovascular outcomes: a network meta-analysis","volume":"14","author":"Admani","year":"2025","journal-title":"Am J Med Open"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1843086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:22:08Z","timestamp":1789719728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1843086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":75,"alternative-id":["10.3389\/fcvm.2026.1843086"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1843086","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1843086"}}